For research use only. Not for therapeutic Use.
Erdafitinib（Cat No.:I001324）is an oral tyrosine kinase inhibitor that targets fibroblast growth factor receptors (FGFR1-4), playing a critical role in cancer cell proliferation and survival. It is primarily used for treating locally advanced or metastatic urothelial carcinoma with susceptible FGFR genetic alterations. By inhibiting FGFR signaling, erdafitinib blocks tumor growth and angiogenesis, offering a therapeutic option for patients with limited treatment alternatives. Its targeted mechanism of action provides a personalized approach to cancer therapy, particularly for those with FGFR-driven malignancies, improving treatment outcomes in advanced cancer stages.
| Catalog Number | I001324 |
| CAS Number | 1346242-81-6 |
| Synonyms | Erdafitinib |
| Molecular Formula | C25H30N6O2 |
| Purity | 98% |
| Target | FGFR1 |
| Target Protein | |
| Solubility | DMSO: ≥ 33 mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | FGFR1：1.2 nM (IC50) |
| IUPAC Name | N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine |
| InChI | InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3 |
| InChIKey | OLAHOMJCDNXHFI-UHFFFAOYSA-N |
| SMILES | CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC |
| Reference | <br /> |
